Table 2 Meta-regression for the association of clinicopathologic factors and the hazard ratio for disease-free and overall survival

 Median age

[8, 9, 11, 13–15, 26–28]

0.098

0.80

 ER positive

[9–11, 13, 15, 23–27]

0.084

0.81

 HER2 positive

[8–11, 14, 15, 23–27]

–0.40

0.22

 Triple negative

[8, 14, 24, 27]

0.05

0.93

 Grade 1 or 2

[8, 10, 14, 15, 23–25]

0.02

0.95

 Grade 3

[8, 10, 14, 15, 23–25]

–0.02

0.95

 Stage 0–I

[9, 13, 23, 25, 27, 28]

0.68

0.14

 Stage II

[9, 13, 23, 25, 27, 28]

–0.30

0.56

 Stage III

[9, 13, 25, 27, 28]

–0.73

0.16

 Metastatic disease

[8–11, 13–15, 24–28]

–0.29

0.35

 Premenopausal

[24, 25]

0.04

0.95

 Nodal involvement

[8–11, 13–15, 23–27]

–0.04

0.90

 NLR cutoff value

[8, 10, 13–15, 23, 24]

–0.29

0.33

 Median follow-up

[8–11, 13, 14, 23, 25–28]

–0.16

0.64

 Median age

[8, 9, 14, 27, 29]

0.06

0.93

 ER positive

[9, 10, 12, 24, 25, 27, 29]

–0.77

0.04*

 HER2 positive

[8–10, 12, 14, 24, 25, 27, 29]

–0.79

0.01*

 Triple negative

[8, 12, 14, 24, 27, 29]

0.63

0.18

 Grade 1 or 2

[8–10, 12, 14, 24, 25, 27, 29]

–0.46

0.21

 Grade 3

[8–10, 12, 14, 24, 25, 27, 29]

0.46

0.21

 Stage 0–I

[9, 25, 27, 29]

0.46

0.54

 Stage II

[9, 25, 27, 29]

0.53

0.36

 Stage III

[9, 25, 27, 29]

–0.50

0.39

 Metastatic disease

[25]

–0.74

0.49

 Premenopausal

[9, 12, 24, 25, 27]

0.43

0.40

 Nodal involvement

[8–10, 12, 14, 24, 25, 27, 29]

0.25

0.52

 NLR cutoff value

[8–10, 12, 14, 24, 25, 27, 29]

–0.15

0.70

 Median follow-up

[8–10, 12, 14, 25, 27, 29]

–0.19

0.66